key: cord-0263330-pmtq2qey
authors: Wilder, Brandon K.; Vigdorovich, Vladimir; Carbonetti, Sara; Minkah, Nana; Hertoghs, Nina; Raappana, Andrew; Cardamone, Hayley; Oliver, Brian G.; Trakhimets, Olesya; Kumar, Sudhir; Dambrauskas, Nicholas; Arredondo, Silvia A.; Camargo, Nelly; Kappe, Stefan H.I.; Sather, D. Noah
title: Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and enhance protection of anti-CSP monoclonal antibodies
date: 2021-10-16
journal: bioRxiv
DOI: 10.1101/2021.10.15.464611
sha: 23c6ebb1c7c0d33d57e7ac2d56750f539274be1f
doc_id: 263330
cord_uid: pmtq2qey

Vaccine-induced sterilizing protection from infection with the Plasmodium parasite, the pathogen that causes malaria, will be an essential tool in the fight against malaria as it would prevent both malaria-related disease and transmission. Stopping the relatively small number of parasites injected by the mosquito before they can migrate from the skin to the liver is an attractive goal. Antibody-eliciting vaccines have been used to pursue this objective by targeting the major parasite surface protein present during this stage, the circumsporozoite protein (CSP). While CSP-based vaccines have recently had encouraging success in disease reduction, this was only achieved with extremely high antibody titers and appeared less effective for a complete block of infection. While such disease reduction is important, these results also indicate that further improvements to vaccines based solely on CSP will likely yield diminishing benefits towards the goal of durable, infection-blocking immunity. Here, we show that monoclonal antibodies (mAbs) recognizing the sporozoite protein TRAP/SSP2 across the major protein domains exhibit a range of inhibitory capacity and that these mAbs can augment CSP-based protection despite delivering no sterile protection on their own. Therefore, pursuing a multivalent subunit vaccine immunization is a promising strategy for improving infection-blocking malaria vaccines.

The last four years have marked a disheartening milestone as the first time in a 2 generation without a reduction in the global burden of malaria (WHO) 1 . The 3

interventions that have provided much of the previous progress, such as insecticide-4 treated bednets and large scale treatment programs, are highly susceptible to 5 interruptions due to political or economic instability. This was starkly illustrated by the 6 resurgence of malaria in Venezuela after near-elimination and also as predicted 7

following the COVID-19 pandemic 1 . Therefore, it is likely that long-lasting, infection-8 blocking interventions (e.g. vaccines, long-lasting monoclonal antibodies or 9 chemoprophylactics) will be required to drive malaria to elimination. 10 11 Developing such an intervention is hampered by the complex life cycle of the parasite, 12 which begins when an infected mosquito injects tens to hundreds of the "sporozoite" 13 forms of the parasite into the dermis 2 . From here, sporozoites actively traverse through 14 multiple cell types in search of an endothelial cell through which they will gain access to 15 the blood 3 . They are carried to the liver within minutes, where they traverse multiple cell 16 types in the liver parenchyma and eventually establish infection in a hepatocyte 4 . 17

Following ~7-10 days of asexual replication and transformation (~2 days in rodent 18 malaria models), each successful liver stage releases 30,000-50,000 "merozoites" that 19 cyclically infect, replicate within and lyse red blood cells 5,6 . It is only during this blood 20 stage of infection when symptomatic disease occurs and is also where a subset of 21 sexually differentiated parasite forms can be picked up by a new mosquito host to 22 continue the transmission cycle. Each step in the infection cycle presents an opportunity 23 for intervention, although vaccines targeting the "pre-erythrocytic" stages in the skin and 1 liver have yielded the most promising results 7 . 2 3

The most advanced pre-erythrocytic vaccine is RTS,S-an antibody-eliciting subunit 4 vaccine targeting the major sporozoite surface protein circumsporozoite protein (CSP) 8 . 5

Vaccines based on attenuated live sporozoites that arrest in the liver and function by a 6 combination of T cells and antibodies have also demonstrated robust protection 9 . 7

Unfortunately, despite significant efficacy from both approaches in controlled human 8 malaria infection (CHMI) studies in malaria-naïve volunteers, both vaccines have 9 markedly reduced efficacy in field trials and have not met the goals of 75-80% 10 protection for vaccines 10 or injectable anti-malarials 11 . Recent encouraging Phase II 11 results with the R21 CSP particle in Matrix-M adjuvant do meet the WHO goal of 75% 12 protection against clinical disease for one year 12 . However, this protection appears less 13 robust in preventing infection and depends on high antibody titers requiring yearly 14 boosters that are vulnerable to the same interruptions as current interventions. These 15 realities highlight the significant room for improvement in both T cell and antibody-16 eliciting vaccines, with the latter more amenable to iterative improvement due to 17 available in vitro and in vivo preclinical assays 13-16 . 18 19 Of the hundreds of proteins expressed at the sporozoite stage, at least 47 are surface-20 exposed [17] [18] [19] and therefore potentially accessible to antibodies. However, few of these 21 proteins have been rigorously investigated for their use in antibody-eliciting vaccines 20 . 22

In addition to CSP, the thrombospondin-related anonymous protein (TRAP, also known 23 as sporozoite surface protein 2 or SSP2) has been pursued as a vaccine candidate due 1 to its high abundance, essentiality for sporozoite infection and correlation with protection 2 in naturally-immune persons 21, 22 . The TRAP ectodomain consists of 3 main domains: a 3 von Willebrand factor A-like domain (vWA), the thrombospondin repeat (TSR) domain 4 and a repeat domain 21 . The most advanced TRAP vaccine candidate is an 5 adenovirus/MVA-vectored vaccine eliciting strong T cell responses that has had low or 6 mixed efficacy results in CHMI trials 23,24 and field trials 25 but has been improved in 7 mice following targeting of the T cell response to the liver 26 . A combination protein 8 TRAP/RTS,S immunization failed to show significant protection 27 , while a fusion-protein 9 approach using TRAP and CSP resulted in complete protection 28 . Antibody function in 10 experiments involving immunization with TRAP-derived peptides yielded mixed results 11 ranging from significant sporozoite inhibition in vitro 29 to no protection in vivo 30 . In 12 summary, the results using TRAP alone or in combination with CSP are difficult to 13 interpret due to the diversity of vaccine platforms used, the possibility of immune 14 interference in studies combining platforms, and the unclear dominance of roles for 15 antibodies and T cells in protection 31 . Whether a more targeted TRAP antibody 16 response could contribute to protection either alone or in combination with CSP remains 17 poorly defined. 18

Here, we used both active immunization and passive transfer of monoclonal antibodies 20 raised against either Plasmodium yoelii (rodent malaria) and Plasmodium falciparum 21 (human malaria) TRAP to more directly explore the potential efficacy of anti-TRAP 22 antibodies. We found that anti-TRAP antibodies modestly prevent liver infection in a 23 manner dependent on the TRAP domain recognized. Importantly, however, we 1 demonstrate proof of concept that anti-TRAP antibodies with minimal protective 2 capacity of their own can augment anti-CSP antibodies, providing additive protection 3 that raises their protective efficacy above the desired threshold of 75-80% protection. 4

Together, these findings argue for further investigation of rationally designed antibody-5 eliciting malaria vaccines that targets multiple antigens and might include CSP as well 6 as non-CSP targets such as TRAP. 7 8 9

PyTRAP polyclonal antibodies can prevent parasite infection of hepatocytes in vitro and 11 in vivo. 12

To elicit potentially functional anti-TRAP antibodies, we generated full-length 13 ectodomains and fragments of both rodent (P. yoelii) and human (P. falciparum) malaria 14 TRAP proteins ( Fig. 1A ; Suppl. Table 1 ) and verified their purity (Fig. 1B) . Serum from 15 mice immunized with the rodent malaria P. yoelii TRAP ectodomain (PyTRAP) 16 recognized Py sporozoites by immunofluorescence in a pattern consistent with 17 micronemal localization, indicating the antigenic fidelity of the recombinant protein (Fig.  18 2A). We further tested this serum in an inhibition of sporozoite traversal and invasion 19 (ISTI) assay. Compared to control serum, anti-PyTRAP serum was able to modestly but 20 significantly (p=0.028) reduce sporozoite invasion of Hepa1-6 hepatoma cells in vitro at 21 a level similar to serum from mice immunized with the recombinant PyCSP ectodomain, 22

although the latter failed to reach significance (p=0.106) (Fig. 2B) . In contrast, 23 sporozoite traversal of Hepa1-6 cells was not affected by anti-PyTRAP serum 1 (p=0.125), whereas anti-PyCSP serum did significantly reduce traversal (p=0.0057) 2 ( Fig. 2C) . The known inhibitory anti-PyCSP mAb 2F6 reduced both inhibition and 3 traversal in this assay as expected ( Fig. 2B and C) . 4 5 PyTRAP-immunized mice were then challenged with Py sporozoites via mosquito bite to 6 determine if these antibodies could function in vivo to reduce liver infection. We utilized 7 a PyGFPluc parasite, which expresses luciferase, enabling the measurement of liver 8 stage parasite burden by bioluminescence imaging. In contrast to mice immunized with 9 a non-specific control protein (Env), which showed no reduction in parasite liver stage 10 burden following challenge compared with naive mice, mice immunized with the 11 PyTRAP ectodomain demonstrated a significant 62% reduction of parasite liver stage 12 burden. Mice immunized with PyCSP ectodomain had a 91% reduction relative to naive 13 controls (Fig. 2D) . Together, these data indicate that anti-PyTRAP antibodies can 14 function in vitro and in vivo to reduce parasite infection of hepatocytes. 15 16 PyTRAP monoclonal antibodies display a diverse array of functions in vitro and can 17 provide additive protection to anti-CSP antibodies in vivo. 18 Serum polyclonal antibodies, as studied above, are a mixture of many antibody 19 specificities, making it difficult to characterize the relative contribution to functional 20 activity of responses directed at different domains. To enable such a characterization of 21 the repertoire of PyTRAP-elicited antibodies, we produced a panel of 15 mAbs. When 22 tested in ISTI at 10, 50 and 100 μg/mL, 12 of these mAbs significantly inhibited invasion 23 or traversal at one or more concentrations, with mAbs TY03 and TY11 showing the 1 most consistent and potent inhibition (Fig. 3A, Suppl. Fig. 1) . 2 3 Overall, the mAbs demonstrated a wide range of binding affinities to recombinant 4 PyTRAP (Fig. 3B , Suppl. Table 2 ) and recognized epitopes in the vWA, TSR and 5 repeat regions (Suppl . Table 3) , thus covering the entire protein ectodomain. Among 6 the 15 mAbs recovered, 10 mAbs bound to the vWA domain. Six of these (TY02, TY05, 7 TY06, TY10, TY11, TY20) shared variable-segment assignments for both heavy and 8 light chains, had closely related complementarity-determining-region (CDR) sequences 9 and had 88.4-96.7% and 93.9-96.9% sequence identity in the variable-region 10 sequences of their heavy and light chain, respectively (Suppl. Table 4 and Suppl. Fig.  11 2). As expected, these antibodies were functionally similar in that they bound 12 specifically to the vWA domain (Suppl. Table 3 ) and inhibited sporozoite infection in 13 vitro (Fig. 3A, Suppl. Fig. 1) . Two mAbs specifically recognized the TSR domain, and 14 the remaining three mAbs bound epitopes in the repeat region (Suppl. Table 3 ). These 15 non-vWA antibodies had only modest or no sporozoite inhibition of infection in vitro (Fig. 16 3A) . This panel of mAbs also showed a wide range of binding kinetics, with all strongly 17 inhibitory mAbs having a kon of >10 5 M -1 s -1 and a kdis of <10 -2 s -1 (Figure 3B , note the 18 red box, Suppl. We next wanted to determine whether an anti-PyTRAP mAb could provide sterilizing 2 protection in vivo on its own or in combination with an anti-CSP mAb. For this, we chose 3 three vWA domain-binding anti-PyTRAP mAbs: TY03 and TY11, which were the top-4 performing mAbs in ISTI, and TY12, which failed to demonstrate efficacy in ISTI. The 5 anti-PyTRAP mAbs were given at 300 μg/mouse (~15 mg/kg) alone or with a partially 6 protective dose of 100 μg/mouse (~5 mg/kg) of anti-PyCSP mAb 2F6 prior to mosquito 7 bite challenge 32 . As shown in Fig. 3C and Table 1 , mice administered anti-PyCSP mAb 8 2F6 showed significant sterile protection, with 9/18 (50%) remaining parasite-free, 9 compared to 2/15 (13.3%) for mice receiving non-specific murine IgG (p=0.032). Neither 10 TY11 nor TY12 showed any protection (2/13 or 15.4% non-infected) despite TY11 11 demonstrating the most robust inhibition in vitro. Administration of the mAb TY03 12 resulted in 7/16 mice (43.7%) remaining parasite-free which did not reach significance 13 (p=0.072). When combined with the anti-CSP mAb, only the addition of TY03 afforded 14 significant sterile protection (87.5% or 14/16 mice) over the control group (p<0.001) 15 which, importantly, was a significant improvement over protection observed with anti-16 PyCSP mAb alone (p=0.025). Together these data indicate that while in vitro testing of 17 mAbs can be useful for identifying non-functional mAbs (e.g. TY12), they should be 18 validated in vivo for function. Importantly, these data provide proof of concept that non-19 CSP antibodies can provide at least additive protection to anti-CSP antibodies, even 20 when those non-CSP antibodies only provide partial levels of protection on their own. 21

Antibodies targeting the human malaria parasite P. falciparum TRAP can function 1 against sporozoite invasion of hepatocytes. 2

We next wanted to determine if antibodies directed against TRAP/SSP2 from the 3 human malaria parasite, P. falciparum, could also function to prevent sporozoite 4 infection. Serum from mice immunized with the ectodomain of P. falciparum TRAP 5 (PfTRAP) was able to recognize Pf sporozoites in IFA (Fig. 4A ) and demonstrated 6 consistent inhibition of Pf sporozoite invasion in vitro at a level similar to serum from 7 mice immunized with the ectodomain of P. falciparum CSP (PfCSP) (Fig. 4B) . Inhibition 8 of sporozoite traversal in vitro was more modest as compared to anti-PfCSP polyclonal 9 serum (Fig. 4C) . The known inhibitory anti-PfCSP mAb 2A10 demonstrated robust 10 inhibition of both invasion and traversal ( Fig. 4A and B) . 11 12 Using a similar approach to the anti-PyTRAP work described above, we isolated 7 anti-13

PfTRAP mAbs from immunized mice. Of these mAbs, 5 recognized the vWA domain 14 and 2 recognized the TSR domains (Suppl. Table 3 the PfTRAP ectodomain (Fig. 5B) . Surprisingly, mAb AKBR-7, which had the best 20 binding properties of the set (Kd ~0.15±0.04 nM, Suppl. Table 2) , demonstrated the 21 worst inhibitory properties (Fig. 5B) . Similar to the case with the anti-PyTRAP mAb 22 panel described above, our data suggest that the PfTRAP vWA domain contains 23 epitopes exposing vulnerability to inhibition, however lack of mAbs that strongly bind 1 other portions of PfTRAP make it difficult to discount the roles that these domains may 2 play in inhibition in vivo. Using this method, we tested the ability of the anti-PfTRAP mAb AKBR-4 to provide 20 sterile protection against Pf mosquito-bite infection alone or in combination with a 21 partially-protective anti-PfCSP mAb CIS43 37 . We chose a dose of 50 μg/mouse (~2.5 22 mg/kg) for each mAb, as this provides partial protection with an anti-PfCSP mAb 37 and 23 gives a serum concentration of ~10 μg/mL at the time of infection, which is achievable 1 by both active vaccination and passive transfer of long-lasting mAbs 42,43 . We previously 2 conducted passive administration, mosquito bite challenge in 2 replicate experiments 37 3 that showed that 50 µg/mouse dose of anti-PfCSP mAb CIS43 was protective (5/7 and 4 5/8 protected in each experiment), compared to control mice (0/7 and 0/7 protected). To 5 avoid unnecessary duplication of FRG huHep experiments, we included those cohorts 6 in our overall analysis of mAbs in this study. We conducted a third replicate experiment 7 with an additional 8 CIS43 mAb mice and 5 control mAb mice in the current study, 8

where 5/8 CIS43 treated mice were protected and 0/5 control mice were unprotected, 9 bringing our total experimental yield to a total of 15/23 protected (65%), which was 10 significant compared to 0/19 of control mice protected (0%, p<0.0001; Table 2 , Fig.  11 5C). This protection was not improved in a single experiment of 5 FRG huHep mice in 12 which the dose was increased 3-fold to 150 μg/mouse (3/5, 60% protected; p=0.002 13 over control). 14 15 On its own, passive administration of 50 μg/mouse of AKBR-4 failed to provide any 16 sterile protection (0/11, 0%). Yet, when 50 μg/mouse of AKBR-4 was combined with 50 17 μg/mouse of the anti-PfCSP mAb (100 μg mAb/mouse total), 14/16 (88%) mice were 18 sterilely protected. The improvement afforded by the AKBR-4/anti-PfCSP mAb 19 combination over the efficacy of the anti-PfCSP mAb alone (up to 65% protection with 20 up to 150 µg/mouse) trended toward, but did not reach statistical significance at this 21 group size (p=0.131), despite still being statistically protective compared to the control 22 antibody treatment (p<0.0001). Nevertheless, together these results strongly support 23 proof of concept that polyclonal and monoclonal antibodies directed against PfTRAP 1 can reduce Pf sporozoite invasion and traversal of hepatocytes in vitro and are able to 2 raise the protective capacity of anti-PfCSP antibodies above the threshold of 75% 3 protection. 4

Discussion 1

Here, we have shown that combining antibodies recognizing TRAP and CSP resulted in 2 an additive protective effect when assessed by a mosquito-bite challenge. To date, the 3 most extensive and clear proof-of-concept that non-CSP antigens can be combined with 4 CSP to provide superior sterile protection was from a recently published rodent malaria 5 study 44 . The protective contributions of antibodies in that study were not specifically 6 investigated, as antibodies were deemed irrelevant for protection compared to the role 7 of T cells. This was determined in the context of a vectored vaccine immunization, 8 which is biased towards the elicitation of T cells, and using an intravenous sporozoite 9 challenge, which has been shown to bypass the role of antibodies in the skin and 10 interstitial tissues 45,46 . Therefore, although promising, this study was not designed to 11 assess the substantial role of antibodies in protection from pre-erythrocytic infection as 12 has been previously reported [45] [46] [47] . However, these findings, along with our data, 13 suggest that enhanced protection over CSP-alone immunization is possible by way of 14 multivalent subunit vaccination targeting distinct sporozoite surface-exposed proteins. with CSP have shown that within a functional polyclonal antibody response, ineffective 1 antibodies may make up the majority and only a subset are potent antibodies 2 distinguished by nuanced binding properties 36, 37, [48] [49] [50] [51] [52] [53] . Understanding these complex 3 activities can identify superior mAb products and vaccine immunogens, yet such studies 4 have not been previously performed for TRAP or other non-CSP pre-erythrocytic 5 antibody targets. Here, we show that the polyclonal antibody response to full-length 6

PyTRAP can substantially reduce parasite infection of hepatocytes in vitro and in vivo. 7

We confirmed these observations using monoclonal antibodies and conclude that this 8 effect is likely driven by vWA and TSR-specific antibodies. These findings clearly 9 support TRAP as a functional antibody target and is in line with previous studies using 10 antibodies against TRAP protein fragments 29 , yet are in contrast to others that failed to 11 see significant inhibition 30 . Our data with PfTRAP were more limited but the only mAb 12 that was functional in vitro recognized the vWA domain. The difference in the 13

proportions of functional antibodies we observed between PyTRAP and PfTRAP may 14 be due to subtle differences in protein localization 54,55 and, potentially, binding partners 15 56 between the two species. 16 17 Achievable and minimal functional antibody levels are important parameters in vaccine 18 and monoclonal antibody product development. In our in vivo Py inhibition studies, the 19 combination of mAbs brought the total antibody dose to four times that of the anti-20

PyCSP antibody alone (100 μg/mouse of anti-PyCSP alone to 400 μg/mouse total with 21 the combination). It is reasonable to expect that simply increasing the dose of the anti-22

CSP mAb would have also yielded higher levels of protection in this mouse model. Yet 23 experience with RTS,S-which elicits extremely high levels of anti-CSP antibodies-as 1 well as published data using highly potent anti-CSP mAbs 37,49,57 suggest that 2 increasing anti-CSP titers alone provides diminishing returns. Furthermore, sustaining 3 such high levels of antibodies over years may be unachievable by vaccines or mAb 4

prophylaxis. The first CHMI trial using passive transfer of the same CIS43 anti-PfCSP 5 mAb used in this study indeed showed that mAbs can provide sterilizing protection 6 against P. falciparum mosquito bite infection at serum concentrations between ~50-500 7 µg/mL. However, prophylactic mAb products will likely need increased potency in order 8 to provide long-lasting protection at lower concentrations against more diverse and 9 likely more fit parasites in the field. Rather than increasing the dose or frequency of 10 administration of anti-CSP mAbs to sustain high levels of serum concentrations, long-11 term maintenance of moderate or low titers against two or more antigens with additive 12 protection properties may be more easily achieved. Our experiments using Pf mosquito-13 bite challenge in FRGhuHep mice support such a strategy, as we were able to achieve 14 high levels of sterile protection (88%) using a combination of anti-PfCSP and anti-15 PfTRAP mAbs. Importantly, this level of protection was achieved using a low total dose 16 of mAb (100 µg/mouse or ~5 mg/kg) and brought the combination above the 75-80% 17 protection threshold desired for vaccines 10 or injectable anti-malarials 11 . Furthermore, 18 our total combination dose of 100 µg/mouse (50 µg/mouse each of anti-PfCSP and anti-19

PfTRAP mAb) gave a total circulating mAb concentration of ~20 µg/mL-a level that 20 can be achieved for ~36 weeks with a single 20 mg/kg injection of long-lasting mAbs 21 42,58,59 or ~4 years via active vaccination 60 . On the other hand, our data showing that 22

tripling the dose of the anti-PfCSP mAb alone (150 µg/mouse, 7.5 mg/kg) failed to 23 improve protection, therefore, suggests that reaching desired thresholds of protection at 1 lower antibody concentrations may be more efficiently achieved by adding additional 2 antibody targets rather than increasing the anti-CSP antibody concentration. 3 4 In summary, we provide proof of concept that antibodies targeting TRAP can contribute 5 to sterile protection when used in combination with anti-CSP antibodies. These findings 6 support vaccine and mAb strategies where multiple antigens are targeted to enhance 7 the protection afforded by CSP. Specifically, we posit that rationally designed non-CSP 8 proteins or mAbs may be powerful tools for eliciting high levels of long-lasting protection 9

at lower antibody titers, as our data suggest they can enhance CSP-based protection 10 even when they do not elicit substantial sterile protection on their own. Such a 11 multivalent approach has previously been hampered by the difficulty in generating and 12 combining multiple protein-in-adjuvant formulations, but may be more easily achieved 13 by the use of mRNA-based vaccines which have proven adept as a multi-antigen 14 vaccine platform in preclinical studies 61,62 . Alternatively, pre-selected, multivalent mAbs 15 could be used as a cocktail, although such an approach is currently limited by cost 63 . 16

Our results indicate that efforts to develop a long-lasting, infection-blocking malaria 17 intervention would greatly benefit from identifying non-CSP antibody targets that 18 enhance CSP-elicited protection. 19 20

Recombinant protein production 2 Recombinant proteins were produced in transiently transfected suspension culture of 3

FreeStyle 293 cells (Thermo), as previously described 64 . Briefly, codon-optimized 4 constructs encoding the ectodomain or deletions of Plasmodium falciparum (PfTRAP) 5

and Plasmodium yoelii TRAP (PyTRAP) were generated as fusions to the 8xHis and 6

AviTag 65 sequences (Table 1) . Following transfection using the high-density PEI 7 method 66 and the subsequent 5-day incubation, cells were removed by centrifugation 8 and the culture supernatants were supplemented with NaCl (+350 mM) and sodium 9 azide (0.02%). Treated culture supernatants were passed by gravity through NiNTA 10 agarose, washed with Wash Buffer (10 mM Tris-HCl, pH 8, 300 mM NaCl, 10 mM 11 imidazole), and eluted with Elution Buffer (10 mM Tris-HCl, pH 7.4, 300 mM NaCl, 200 12 mM imidazole). Further purification was performed by size-exclusion chromatography 13 using a calibrated Superdex 200 (10/600) column. The HIV Env gp120 control protein 14 was produced, as previously described 67 . 15

Monoclonal antibody cloning and production 17

Monoclonal antibodies were cloned and produced, as previously described 64 . Briefly, 18 ectodomain PfTRAP and PyTRAP constructs were used as immunogens, and their 19 biotinylated versions were used to isolate antigen-specific B cells by flow cytometry. 20

Following culture, wells containing B cells producing antigen-binding IgG were identified 21 by ELISA, immunoglobulin-encoding transcripts were amplified by RT-PCR and used for 22 the generation of heavy-and light-chain constructs for recombinant mAb expression. 23

The sequences were annotated using IgBLAST 68 . 24

To express recombinant mAbs, the plasmid DNA was used to transfect suspension 1 cultures of FreeStyle 293 cells (Thermo), as described above. After five days in culture, 2 cells were removed by centrifugation and the cultures were supplemented with NaCl 3 (+350 mM) and sodium azide (0.02%). Treated culture supernatants were passed by 4 gravity through Protein G resin equilibrated in Wash Buffer (10 mM HEPES, pH 7, 300 5 mM NaCl, 2 mM EDTA), washed with Wash Buffer, and eluted with 100 mM glycine, pH 6 2.7. Resulting eluates were buffer-exchanged by repeated centrifugal ultrafiltration with 7

HBS-E (10 mM HEPES, pH 7, 150 mM NaCl, 2 mM EDTA). Mice immunized with Pf proteins were immunized as above with the exception that mice 4 were additionally boosted with IV protein three days prior to sacrifice and collection and 5 cryopreservation of splenocytes. 6

For both, serum was collected from immunized mice by collecting whole blood in BD 7 microtainer serum tubes, allowing blood to clot at room temperature for at least 30 8 minutes and then centrifuged according to manufacturer's instructions to separate 9 serum for storage and use in in vitro assays. 10 11 Sporozoite immunofluorescence microscopy 12 Fresh-dissected Py or Pf sporozoites were stained, as previously published 71 . Briefly, 13 fresh-dissected Py or Pf sporozoites were fixed with 4% PFA and air-dried onto glass 14 slides overnight. These were then permeabilized with 0.1% Triton-X and stained with 15 polyclonal (serum at 1:200 dilution) or monoclonal (10 µg/mL) antibodies. Sporozoites 16 were identified by co-staining with either anti-MTIP or anti-CSP mAbs as well as DAPI 17 for nuclear localization. Images were acquired using an Olympus IX-70 DeltaVision 18 deconvolution microscope at 100X magnification. 19 20

In vitro ISTI was performed, as previously published for both Py 45 and Pf 14 . Briefly, 22

fresh-dissected sporozoites were added to hepatoma cells (Hepa1-6 for Py and HC04 23 for Pf) plated the day prior in 96-well plates in the presence of antibodies and FITC-1 dextran in technical duplicates or triplicates. After 90 minutes, cells were fixed, 2 permeabilized and stained with fluorescently-labeled anti-CSP mAbs and analyzed by 3 flow cytometry. Invaded cells were identified by the presence of CSP and traversed 4 cells by the uptake of FITC-dextran. Within each experimental replicate, antibody-5 treated wells were normalized to the invasion and traversal of wells treated with pre-6 immune serum or non-specific mouse IgG which was set to 100%. We would like to thank the vivarium staff at Seattle Children's Research Institute for 2 their support of animal studies. We would also like to thank Drs. Nevile Kisalu and 3

Robert Seder of the NIH VRC for their provision of monoclonal antibody CIS43. This 4 study was funded by NIH R01 AI117234 to DNS and SHK. 5 

Tables 1 Table 1 

Mice were injected with 100 μg/mouse of anti-CSP mAb (2F6), 300 μg/mouse of an 6 anti-PyTRAP mAb or a combination of both 24h prior to challenge by 5 Py-infected 7 mosquitos. Where only one mAb was injected, mice were also given non-specific mIgG 8

to total 400 µg/mouse. Mice were tracked for 14 days for parasitemia by thin blood 9 smear and those which remained parasite-free at day 14 were considered sterilely 10 protected. Comparisons between groups were carried out via Barnard's exact test with 11 the resulting p-value, as indicated. 12 Mice were injected with indicated doses of either non-specific mIgG, anti-CSP mAb 5 CIS43, anti-PfTRAP mAb AKBR-4 or a combination of anti-CSP and AKBR-4 24h prior 6

to challenge with 5 Pf-infected mosquito bites. Mice were injected with human red blood 7 cells at day 5 and 6, and then blood sampled at days 7 and 9 to detect blood stage 8 parasitemia by qPCR. Number and percentages of mice protected across 3 9

independent experiments are shown. The p values for comparisons to either control 10 group (mIgG) or anti-CSP alone using Barnard's exact test are shown. # indicates 11 results previously reported in Kisalu et al. 49 . 12 Mice were immunized three times with PyTRAP and PyCSP ectodomains. A) Immune 4 serum was used to verify binding to Py sporozoite via immunofluorescence. Shown are 5 fixed, permeabilized sporozoites labeled with a 1:800 dilution of polyclonal mouse 6 serum followed by anti-mouse IgG (red channel) and DAPI nuclear stain (blue). Immune 7 serum was then assessed for function in vitro for inhibition of invasion (B) and traversal 8 (C). In B and C, each data point is the average "% of pre-immune" invasion or traversal 9

for pooled serum from a cohort of 5 mice across independent assays (number shown 10 above each bar). Each bar indicates the mean "% of pre-immune" parasite invasion or 11 traversal with percent change from 100% (shown as dashed line) shown above. 12

Asterisks indicate a significant difference from 100% as determined by a two-tailed one-13 sample t-test. D) Immunized mice were challenged by the bite of 15 PyGFPluc-infected 14 mosquitos and assessed for parasite liver burden by bioluminescent imaging. Each data 15 point represents an individual mouse with each color corresponding to an independent 16 immunization-challenge experiment (total number of animals shown above each bar). 17

Each data point is normalized to the mean luminescent signal from "naive" mice within 18 each challenge experiment while "control" mice are an additional group immunized with 1 HIV Env gp120 protein. In each case, mean values of % inhibition (i.e., 100% -invasion or traversal value) from 4 the 100-µg/mL mAb concentrations (bar plots with these and additional conditions 5 shown in Suppl. Fig. 1 ) are represented on a color axis. Binding kinetics for each mAb 6 was measured by BLI and shown as kinetic maps (B) with gray dashed diagonal 7 contour lines labeled with the corresponding Kd values and symbols representing the 8 characterized epitopes for invasion (left) and traversal (right) inhibition. Higher-affinity 9 (i.e., those possessing lower Kd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number of animals in each group is shown below the corresponding bar, individual 16 values shown in Table 1 ). 17 1 Figure 4 . Polyclonal antibodies to PfTRAP inhibit parasite invasion, traversal in vitro. 2 Mice were immunized three times with full-length PfTRAP and PfCSP. A) Immune 3 serum was used to verify binding to Pf sporozoite via immunofluorescence. Shown are 4 fixed, permeabilized sporozoites labeled with a 1:800 dilution of polyclonal mouse 5 serum followed by anti-mouse IgG (green channel), anti-PfCSP monoclonal antibody 6 2A10 (red channel, right image) and DAPI nuclear stain (blue, right image). Immune 7 serum was then assessed for function in vitro for inhibition of invasion (B) and traversal 8 (C). In B and C, each data point is the average % of Pre-immune invasion or traversal 9 from technical triplicates"$."$./3&3./3.;"3K&38$53.;%)"P-9<"7-8"$./$9-;3%";<3"53-."D":?" 10 Q83=$552.3"&-8-%$;3"$.0-%$:.":8";8-038%-1"R@PS"M$;<"3K-9;"53-."-7:03)"6%;38$%L%" 11 $./$9-;3"-"%$>.$?$9-.;"/$??383.93"?8:5",((D"-%"/3;385$.3/"7A":.3=M-A";";3%;"M<383"#"$%" In each case, mean values of % inhibition (i.e., 100% -invasion or traversal value) from 4 the 100-µg/mL mAb concentrations (bar plots with these and additional conditions 5 shown in Suppl. Fig. 3 ) are represented on a color axis. Binding kinetics for each mAb 6 was measured by BLI and shown as kinetic maps (B) with gray dashed diagonal 7 contour lines labeled with the corresponding Kd values and symbols representing the 8 characterized epitopes for invasion (left) and traversal (right) inhibition. Higher-affinity 9 (i.e., those possessing lower Kd"0-123%4"567%"-83"91:%38";:";<3"2&&38=8$><;"9:8.38":?";<$%" 10

@255-8$N3/"%;38$13"&8:;39;$

3K&38$53.;%"OC; number of animals in each group is shown below the 14 corresponding bar

The authors declare no competing interests. 2